Al Khobar

Fordyce spots are harmless sebaceous glands commonly found on the lips and vermilion border, often causing cosmetic concerns. Researchers are evaluating the safety and effectiveness of a 1726-nm sebaceous-targeting diode laser Accure4 for treating these spots in a prospective pilot study. The study aims to assess improvements in appearance, patient satisfaction, and any side effects over several months. Participants will receive 2 to 3 laser treatment sessions spaced four weeks apart, using the Accure4 device which selectively targets sebaceous glands with temperature-guided, multi-pulse energy and continuous cooling. Treatments focus on the entire affected lip and vermilion area. Follow-up visits will occur at Weeks 4, 8, 12, and 24. An optional additional follow-up at Month 12 will observe longer-term effects without further treatment. During the study, participants will undergo assessments to count the number of Fordyce spots, rate global aesthetic improvements, and record satisfaction levels. Safety and tolerability will be monitored through Week 24, with extended safety observations at Month 6. Participants who opt out of the Month 12 visit will complete the study after Week 24, with no further contact beyond usual care. The total study duration includes treatment and follow-up visits over approximately six months, with optional extended observation.

Researchers are evaluating the efficacy and safety of elecoglipron, an oral tablet taken once daily, for weight management in adults with obesity or overweight. This Phase III global, randomized, double-blind, placebo-controlled trial includes two independent pivotal studies one in adults without type 2 diabetes T2DM and the other in adults with T2DM, all having at least one weight-related health condition. The goal is to understand how elecoglipron compares to placebo when combined with diet and exercise. Participants will be randomly assigned to receive either one of two doses of elecoglipron or a matching placebo daily. Study 1 involves about 3000 adults living with obesity or overweight without T2DM, while Study 2 involves about 1500 adults with obesity or overweight and T2DM. Both studies last 72 weeks, during which changes in body weight and other health measures will be monitored. During the trial, participants will undergo regular health assessments including measurements of body weight, waist circumference, blood sugar control, blood pressure, and other related health indicators. Researchers will track percent change in body weight from baseline at 72 weeks as the primary outcome. Participants will be monitored closely throughout the study to assess safety and effectiveness of the treatment in managing weight and associated health conditions.

Researchers are investigating the effectiveness of transcutaneous tibial nerve stimulation TTNS, a non-invasive treatment, for managing bladder storage symptoms in people with multiple sclerosis MS. MS often leads to neurogenic lower urinary tract dysfunction, causing symptoms like urinary frequency and urgency that negatively affect quality of life. This study aims to compare TTNS with a sham treatment to provide strong evidence on its impact on bladder symptoms and quality of life for people with MS. Participants will be randomly assigned to either an active TTNS group or a sham TTNS group. The active group will receive electrical stimulation on the medial side of the foot targeting the tibial nerve, while the sham group will have stimulation on the lateral side of the foot away from the nerve. Both groups will undergo 18 sessions over 6 weeks, with stimulation three times per week for 30 minutes each session. The devices will be pre-programmed to deliver consistent stimulation parameters. During the study, participants will complete questionnaires and bladder diaries to monitor bladder symptoms, quality of life, and sleep quality at the start, at 6 weeks, and 6 months post-intervention. The primary outcomes include the International Consultation of Incontinence Questionnaire for Overactive Bladder and bladder diaries. Researchers will also evaluate participants perceptions of change. The total participation duration includes follow-up assessments to monitor lasting effects and safety.

Researchers are studying women diagnosed with endometrial cancer to understand how often the cancer returns after receiving standard treatment and to monitor the occurrence of lymphedema, a potential side effect. The study focuses on patients with endometrioid adenocarcinoma undergoing surgery including hysterectomy and sentinel lymph node biopsy, aiming to track outcomes over time. Participants will have surgery involving hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node mapping confirming no malignancy in the lymph nodes. After surgery, those in the study cohort will be followed clinically for relapse with physical exams at post-operative visits for up to 30 months. During the study, participants will undergo regular physical examinations and clinical follow-up visits to check for cancer recurrence and monitor for lymphedema. Researchers will measure the incidence of pelvic or non-vaginal cancer recurrence within 36 months. Participants will be observed for up to 30 months after surgery, with detailed monitoring of symptoms and outcomes throughout the follow-up period.